Chen-Liang, Tzu-HuaMartín-Santos, TaidaJerez, AndrésRodríguez-García, GuillermoSenent, LeonorMartínez-Millán, CristinaMuiña, BegoñaOrero, MayteTeruel, AnabelMartín, AlejandroGómez-Espuch, JoaquínKennedy, KyraBenet, CarmenRaya, José MaríaFernández-González, Martade la Cruz, FátimaGuinot, MartaVillegas, CarolinaBallester, IsabelBaile, MónicaMoya, MaríaLópez-Jiménez, JavierFrutos, LauraNavarro, José LuisUña, JonFernández-López, RosaIgua, CarolinaContreras, JoséSánchez-Vañó, RaquelCozar, María Del PuigTamayo, PilarMucientes, JorgeSánchez-Blanco, José JavierPérez-Ceballos, ElenaOrtuño, Francisco José2023-01-252023-01-252017-09-27http://hdl.handle.net/10668/11625Several studies have reported uneven results when evaluating the prognostic value of bone marrow biopsy (BMB) and PET/CT as part of the staging of diffuse large B-cell lymphoma (DLBCL). The heterogeneity of the inclusion criteria and not taking into account selection and collinearity biases in the analysis models might explain part of these discrepancies. To address this issue we have carried a retrospective multicenter study including 268 DLBCL patients with a BMB and a PET/CT available at diagnosis where we estimated both the prognosis impact and the diagnostic accuracy of each technique. Only patients treated with R-CHOP/21 as first line (n = 203) were included in the survival analysis. With a median follow-up of 25 months the estimated 3-year progression-free survival (PFS) and overall survival (OS) were 76.3% and 82.7% respectively. In a multivariate analysis designed to avoid a collinearity bias with IPI categories, BMB-BMI [bone marrow involvement](+) (HR: 3.6) and ECOG PS > 1 (HR: 2.9) were independently associated with a shorter PFS and three factors, age >60 years old (HR: 2.4), ECOG PS >1 (HR: 2.4), and abnormally elevated B2-microglobulin levels (HR: 2.2) were independently associated with a shorter OS. In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BMB complemented performance status in predicting those patients with a higher risk for relapse or progression. In this cohort BMI by PET/CT could not independently predict a shorter PFS and/or OS.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Bone marrow biopsyPET/CTdiffuse large B-cell lymphomaoutcomes researchAdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHealth StatusHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMultivariate AnalysisPositron Emission Tomography Computed TomographyPredictive Value of TestsPrednisoneRetrospective StudiesRituximabSurvival RateVincristineYoung Adultbeta 2-Microglobulinresearch article28960797open access10.1002/cam4.12052045-7634PMC5673915https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.1205https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673915/pdf